Treatment with Wegovy (semaglutide), the investigational oral semaglutide and Zepbound (tirzepatide) was deemed cost-effective with increased quality of life and fewer cardiovascular events, according to a preliminary draft evidence report from The Institute for Clinical and Economic Review (ICER) on comparative effectiveness and value.

But researchers raised concerns about the affordability of these three GLP-1 drugs to treat patients with obesity. Although the prices of the three drugs studied fall within accepted cost-effectiveness thresholds, widespread demand creates enormous budget pressures on payers, employers, and patients. At current prices, ICER researchers estimate that fewer than 1% of eligible patients could be treated before crossing the ICER budget impact threshold of $880

See Full Page